JLBC
PTLA

J.L. Bainbridge & Co’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

J.L. Bainbridge & Co’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-7,434
Closed -$199K – 94
2019
Q3 		$199K Hold
7,434
– – 0.03% 75
2019
Q2 		$202K Buy
+7,434
New +$233K 0.03% 67

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

J.L. Bainbridge & Co's PTLA Position: Q4 2019 in Review

J.L. Bainbridge & Co sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q4 2019, closing a stake of 7,434 shares — an estimated $199K sold.

J.L. Bainbridge & Co first reported a position in PTLA in Q2 2019 and held it in 2 quarters. The position peaked at $202K in Q2 2019. 224 funds tracked by Wall St. Rank hold PTLA as of Q4 2019.

  • J.L. Bainbridge & Co reported no remaining Portola Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
  • J.L. Bainbridge & Co sold 7,434 Portola Pharmaceuticals, Inc. shares in Q4 2019, an estimated $199K.
  • J.L. Bainbridge & Co first reported a position in Portola Pharmaceuticals, Inc. in Q2 2019 and held it in 2 quarters.
  • J.L. Bainbridge & Co's Portola Pharmaceuticals, Inc. position peaked at $202K in Q2 2019.
  • 224 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q4 2019.

Based on J.L. Bainbridge & Co's 13F filing for Q4 2019, filed 13 Feb 2020.